

Kimberly C. Claeys, PharmD, PhD

CURRICULUM VITAE

Associate Professor Infectious Diseases
Department of Pharmacy Practice, Science
and Health Outcomes Research
University of Maryland School of Pharmacy

20 N Pine Street, Baltimore, MD 21201
Office: N432
Office Phone: 410.706.3215
Email: kclaeys@rx.umaryland.edu

PROFESSIONAL APPOINTMENTS

Associate Graduate Faculty University of Maryland Graduate School, Baltimore, MD	04/2022 – present
Scholar in Diagnostic Excellence National Academy of Medicine (NAM), Washington, DC	06/2022 – 06/2023
Associate Professor – Infectious Diseases Department of Pharmacy Practice, Science, and Health Outcomes University of Maryland School of Pharmacy, Baltimore, MD	07/2021 – present
Investigator - Center for Innovation in Diagnosis University of Maryland School of Medicine, Baltimore, MD	05/2021 – present
Assistant Professor – Infectious Diseases Department of Pharmacy Practice and Science University of Maryland School of Pharmacy, Baltimore, MD	03/2016 – 07/2021
Infectious Diseases Clinical Pharmacy Specialist Antimicrobial Stewardship Improving Clinical Outcomes Team University of Maryland Medical Center, Baltimore, MD	07/2016 – present

EDUCATION & PROFESSIONAL TRAINING

Doctor of Philosophy – Epidemiology Department of Epidemiology and Public Health University of Maryland School of Medicine, Baltimore, MD Dissertation: Diagnostic Stewardship to Improve Diagnosis of Urinary Tract Infections Advisor: Daniel J. Morgan, MD, MS	09/2017 – 12/2022
Graduate Certificate in Public Health Department of Family Medicine and Public Health Sciences Wayne State University School of Medicine, Detroit, MI	07/2013 – 05/2015
Post-Doctoral Infectious Diseases Health Outcomes Fellowship Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI Program Director: Michael J. Rybak, PharmD, MPH, PhD	07/2013 – 02/2016
ASHP- Accredited PGY1 Pharmacy Residency Department of Pharmacy Practice University of Illinois at Chicago College of Pharmacy, Chicago, IL Program Director: Frank P. Paloucek, PharmD, DABAT	07/2012 – 07/2013

Doctor of Pharmacy
Eugene Applebaum College of Pharmacy and Health Sciences
Wayne State University, Detroit, MI

09/2008 – 05/2012

INSTITUTIONAL SERVICE

University of Maryland Medical System

Sepsis Diagnostic Testing Working Group, Co-Chair	2021 – present
System Sepsis Steering Group, Member	2021 – present
Diagnostic Testing in Sepsis Working Group, Member	2019 – 2021

University of Maryland Medical Center

Diagnostic Stewardship Liaison to Antimicrobial Stewardship Team	2024 – present
Clinical Microbiology Fellowship, Program Co-Coordinator	2019 – present
Antimicrobial Stewardship Clinical Outcomes Team, Member	2017 – 2023
Antimicrobial Subcommittee, Member	2016 – present

University of Maryland School of Pharmacy

Academic Admissions Committee, Member	2022 – present
Pharmacy Practice and Science Faculty Search Committee, Member	2022
Experiential Learning Committee, Chair	2021 – 2022
Experiential Learning Committee, Chair Elect	2019 – 2021
PGY2 Infectious Diseases Pharmacy Residency Advisory Committee, Member	2017 – present
Research and Entrepreneurship Executive Committee, Member	2016 – 2018
Pharmacometrics Faculty Search Committee, Member	2018
Department Strategic Planning Research Committee, Member	2016 – 2020
Residency Research Committee, Member	2016 – 2017
Pharmacotherapy Pathway Committee, Member	2016 – 2022

PROFESSIONAL SERVICE

Research Committee Member

Society of Infectious Diseases Pharmacy (SIDP)	02/2024 – present
------------------------------------------------	-------------------

Antimicrobial Stewardship Committee, Member

Society for Healthcare Epidemiology of America (SHEA)	02/2024 – present
-------------------------------------------------------	-------------------

Scientific Review Committee

Katholieke Universiteit (KU) Leuven, Belgium	04/2023
----------------------------------------------	---------

Urinary Tract Infections (UTI) Clinical Algorithm Development Team

Infectious Diseases Society of America (IDSA) & Centers for Disease Control and Prevention (CDC)	01/2023 – present
--------------------------------------------------------------------------------------------------	-------------------

Editorial Board Member

<i>Infectious Diseases and Therapy</i> Journal	05/2022 – present
------------------------------------------------	-------------------

Board Certified Infectious Diseases Pharmacists (BCIDP) Faculty

Society of Infectious Diseases Pharmacy (SIDP)	05/2022
------------------------------------------------	---------

Antimicrobial Stewardship Online Educational Primer Reviewer Society for Healthcare Epidemiology of America (SHEA)	03/2022 – 03/2023
Diagnostic Stewardship Task Force (SIDP Representative) Society for Healthcare Epidemiology of America (SHEA)	01/2022 – present
Guest Editor <i>Antibiotics</i> Journal; Key Collaborations between Antimicrobial Stewardship & Clinical Microbiology	05/2021 – 12/2022
Abstract Reviewer - IDWeek Conference	06/2021, 06/2023
2021 PSAP Infectious Disease Book Expert Reviewer Board of Pharmacy Specialties (BPS)	12/2020
Section Editor - Antimicrobial Development & Drug Resistance <i>Current Infectious Disease Reports Journal</i>	08/2018 – present
Research Committee Member Society for Healthcare Epidemiology of America (SHEA)	04/2018 – 12/2020
Research Committee Member Society of Infectious Diseases Pharmacy (SIDP)	09/2017 – 08/2022
Publications Committee Member Society of Infectious Diseases Pharmacy (SIDP)	09/2016 – 09/2017
Board-Certified Pharmacotherapy Specialist (BCPS) Exam Passing Point Committee Member Board of Pharmacy Specialties (BPS)	05/2016

PROFESSIONAL ADVISORY BOARD MEMBER

bioMérieux Data Analytics	10/2022
LabSimply	10/2022
Duke Margolis Center for Health Policy - Bacterial Diagnostic Testing	06/2022
AbbVie Biopharmaceuticals	05/2022
Melinta Therapeutics	05/2022
La Jolla Pharmaceuticals	05/2022

REFeree FOR SCIENTIFIC JOURNALS

<i>JAMA Network Open</i>	2024 – present
<i>American Journal of Emergency Medicine</i>	2024 – present
<i>Lancet ID</i>	2023 – present
<i>Expert Review of Anti-Infective Therapy</i>	2021 – present
<i>International Journal of Antimicrobial Agents</i>	2021 – present
<i>Clinical Infectious Diseases</i>	2020 – present
<i>British Journal of Clinical Pharmacology</i>	2019 – present
<i>Journal of the American College of Clinical Pharmacy</i>	2018 – present

<i>Open Forum Infectious Diseases</i>	2018 – present
<i>Diagnostic Microbiology and Infectious Diseases</i>	2017 – present
<i>BMC Infectious Diseases</i>	2017 – present
<i>Journal of Clinical Microbiology</i>	2017 – present
<i>Antimicrobial Agents and Chemotherapy</i>	2017 – present
<i>Pharmacotherapy</i>	2016 – present
<i>Infectious Diseases and Therapy</i>	2015 – present

FUNDED RESEARCH GRANTS & CONTRACTS

Potential benefits of decentralized rapid phenotypic AST Vs. Current Standard of care (SOC) in patient management with Gram Negative Blood Stream Infections (G- BSI) QLinea AB (\$136,700), PI Luethy (Co-investigator, 5% effort)	06/2024 – 0/2026
Leveraging pharmacists to improve infectious diseases diagnosis Accelerated Translational Incubator Pilot (ATIP): Innovative Collaboration, University of Maryland Baltimore, (\$40,000), PI Claeys (5% effort)	05/2024 – 05/2025
Optimizing the outcomes of adults with gram-negative bloodstream infections Patient-Centered Outcomes Research Institute (PCORI) (\$13,658,353) PIs Tamma and Cosgrove, Site PIs Claeys (10% effort) and Harris	04/2022 – 11/2027
Using an electronic health record (EHR)-based diagnostic stewardship intervention to optimize the treatment of respiratory viral infections including COVID-19 Centers for Disease Control and Prevention (CDC) - Safety and Healthcare Epidemiology Prevention Research Development (SHEPheRD) Program (\$725,717), PI Morgan (Co-investigator, 10% effort)	08/2022 – 08/2024
Engaging antimicrobial stewardship pharmacists in diagnostic excellence for urinary tract infections Gordon and Betty Moore Foundation (\$35,000), PI Claeys (10% effort)	06/2022 – 06/2023
Prevention Epicenters Program: Protecting Patients from Infections, Antibiotic Resistance and Other Adverse Events (1 U54CK000615-01-00) Centers for Disease Control and Prevention (CDC) - Epicenters for the Prevention of Healthcare-Associated Infections (\$5,920,125), PI Harris (Co-Investigator, 5% effort)	06/2021 – 05/2026
Implementation of clinical decision support to optimize time to effective therapy in multi-drug resistant <i>Pseudomonas</i>: Crossroads of antimicrobial and diagnostic stewardship Merck and Co. (\$58,264), PI Claeys (7.5% effort)	11/2020 – 05/2023
Diagnostic stewardship as a 'nudge' to reduce inappropriate antibiotic use for urinary tract infections (1I01HX002906-01A1) Department of Veterans Affairs Veterans Affairs HSR & D Scientific Merit Program (\$1,155,942), PI Morgan (Co-investigator, 5% effort)	11/2020 – 09/2024
Comparing the clinical utility of rapid diagnostics for the treatment of bloodstream infection using DOOR-MAT GenMark Diagnostics (\$119,600 supplies), PI Claeys (10% effort)	11/2018 – 03/2021

Maryland Statewide Prevention and Reduction of <i>C. difficile</i> (SPARC) Collaborative Maryland Department of Health (\$769,743), PI Leekha (Co-investigator, 15% effort)	09/2018 – 12/2020
Comparing the clinical utility of rapid diagnostics for the treatment of bloodstream infection The Society of Infectious Diseases Pharmacists (\$10,000), BioFire Diagnostics LLC (\$163,790 supplies), PI Claeys (5% effort)	01/2018 – 01/2020
Improving antibiotic use in long term care patients in Maryland through implementation of core antibiotic stewardship principles Maryland Department of Health and Mental Hygiene (\$200,000), PI Brandt	01/2018 – 06/2019
Evaluation of reflex urine culture policies to improve antimicrobial use within the VA CREATE Practice Based Research Network (PBRN) Centers for Disease Control and Prevention (CDC) CREATE PBRN (\$29,212), PI Claeys	04/2017 – 12/2019
Oral vancomycin plus intravenous metronidazole for severe <i>Clostridium difficile</i> NAP1/BI/027 infection ACCP Mentored Resident Research Grants (\$4,564), PI Claeys	09/2017 – 03/2019
Design and implementation of a novel interactive application to enhance learning of antimicrobial spectrum of activity University of Maryland School of Pharmacy Disruptive Innovation Competition (\$50,000), PIs Claeys, Heil, Pandit	06/2017 – 06/2019
Improving clinical outcomes in gram-negative bacteremia through a 24-hour multidisciplinary Verigene® gram-negative blood culture treatment pathway Making a Difference in Infectious Diseases (\$27,222), PI Claeys	06/2017 – 06/2019
Derivation and validation of a risk assessment tool for methicillin-resistant <i>S. aureus</i> acute bacterial skin and skin structure infections (ABSSSIs) Bayer International (\$194,645), PI Rybak	12/2014 – 02/2016
Improving hospital-based antimicrobial prescribing through a multi-system review of antibiotic utilization patterns Michigan Department of Community Health (\$260,263), PI Rybak	01/2014 – 10/2014
Patient outcomes and burden of illness of Gram-negative lower respiratory infections in intensive care units Cubist Pharmaceuticals/Merck (\$151,996), PI Rybak	09/2013 – 06/2016
Impact of early daptomycin versus vancomycin therapy for bloodstream infection caused by methicillin-resistant <i>S. aureus</i> Cubist Pharmaceuticals/Merck (\$177,792), PI Rybak	07/2013 – 11/2015
Prospective evaluation of clinical and economic outcomes of ceftaroline for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) documented or at risk of methicillin-resistant <i>S. aureus</i> Forest Laboratories/Actavis (\$363,815), PI Rybak	07/2013 – 02/2016

SUBMITTED AND PENDING GRANTS AND CONTRACTS

Diagnostic Stewardship Center (DiSC) for antibiotic optimization and HAI reduction VA Patient Safety Center of Inquiry (\$400,000), PI Morgan	09/2024
Improving Care for Older Adults Suspected of Having a UTI Society to Improve Diagnosis in Medicine Seed Grant Program (\$100,000), PI Claeys	05/2024

TEACHING EXPERIENCE

Course Management - University of Maryland School of Pharmacy	
PHMY513 Case-Based Infectious Diseases	2018 – present
PHAR525 Immunology	2018 – 2023
APPC 476 Advanced Practice Patient Care Elective/ID	2018 – present
Lecturer - University of Maryland School of Medicine	
PREV600 – Introduction to Epidemiology	2023 – present
Lecturer - University of Maryland School of Pharmacy	
PHAR5018 Professional Life After Graduation	2017 – 2020
PHMY513 Case-Based Infectious Diseases	2017 – present
PHAR569 Pharmacotherapy I	2016 – present
PHAR570 Pharmacotherapy II	2016 – 2019
PHAR5017 Infectious Diseases Therapeutics II	2016 – present
PHAR5016 Infectious Diseases Therapeutics I	2016 – present
Facilitator - University of Maryland School of Pharmacy	
PHMY539 Special Projects	2016 – present
Presenter - University of Maryland Medical Center	
PGY1/PGY2 Orientation	2017 – present
Preceptor - University of Maryland Medical Center	
Clinical Microbiology Fellow Antimicrobial Stewardship rotation	2020 – present
PGY2 ID Pharmacy Residency Research rotation	2017 – present
PGY2 ID Pharmacy Residency Antimicrobial Stewardship rotation	2017 – present
PGY1 Pharmacy Practice Residency Antimicrobial Stewardship rotation	2017 – 2022
Medical ID Fellows Antimicrobial Stewardship rotation	2016 – present

PEER-REVIEWED PUBLICATIONS (N = 88)

1. Redwood R, **Claeys KC**. The Diagnosis and Treatment of Adult Urinary Tract Infections in the Emergency Department. *Emerg Med Clin North Am*. 2024 [epub ahead of print].
2. Coffey KC, **Claeys K**, Morgan DJ. Diagnostic Stewardship for Urine Cultures. *Infect Dis Clin North Am*. 2024 Apr 3:S0891-5520(24)00006-0. doi: 10.1016/j.idc.2024.03.004. Epub ahead of print. PMID: 38575490.
3. Singh HK, **Claeys KC**, Advani SD, Ballam YJ, Penney J, Schutte KM, Baliga C, Milstone AM, Hayden MK, Morgan DJ, Diekema DJ. Diagnostic stewardship to improve patient outcomes and healthcare-associated

- infection (HAI) metrics. *Infect Control Hosp Epidemiol*. 2024 Apr;45(4):405-411 Epub 2024 Jan 11. PMID: 38204365.
4. Kunz Coyne AJ, Alosaimy S, Lucas K, Lagnf AM, Morrisette T, Molina KC, DeKerlegand A, Schrack MR, Kang-Birken SL, Hobbs AL, Agee J, Perkins NB 3rd, Biagi M, Pierce M, Truong J, Andrade J, Bouchard J, Gore T, King MA, Pullinger BM, **Claeys KC**, Herbin S, Cosimi R, Tart S, Veve MP, Jones BM, Rojas LM, Feehan AK, Scipione MR, Zhao JJ, Witucki P, Rybak MJ. Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. *Microbiol Spectr*. 2024 Jan 11;12(1): e0235123. PMID: 38018984.
 5. Advani SD, **Claeys KC**. Behavioral Strategies in Diagnostic Stewardship. *Infect Dis Clin North Am*. 2023 Dec;37(4):729-747Epub 2023 Aug 1. PMID: 37537001.
 6. Zou I, Abate D, Newman M, Heil EL, Leekha S, **Claeys KC**. Crossroads of Antimicrobial and Diagnostic Stewardship: Assessing Risks to Develop Clinical Decision Support to Combat Multidrug-Resistant Pseudomonas. *Open Forum Infect Dis*. 2023 Oct 12;10(10):ofad512. PMID: 37901124.
 7. Baghdadi JD, Tripathi R, Pineles L, Harris AD, Palacio D, Charles D, **Claeys KC**, Heil E, Bork J, Morgan DJ. Developing a diagnosis calculator to estimate the probability of bacterial pneumonia. *Antimicrob Steward Healthc Epidemiol*. 2023 Aug 7;3(1):e137. PMID: 37592970.
 8. Morgan DJ, Leekha S, **Claeys KC**. Increasing Evidence That Diagnostic Stewardship May Improve Antibiotic Use. *JAMA Intern Med*. 2023 Sep 1;183(9):942-943
 9. Baghdadi J, Tripathi R, Pineles L, Harris A, Palacio D, Charles, D, **Claeys KC**, Heil E, Bork J, Morgan D. Developing a diagnosis calculator to estimate the probability of bacterial pneumonia. *Antimicrob Steward Healthc Epidemiol*. 2023 Aug 7;3(1):e137, 2023.PMID: 37592970.
 10. Coffey KC, **Claeys KC**, Morgan DJ. Diagnostic stewardship: what impacts antibiotics use? *Curr Opin Infect Dis*. 2023 Aug 1;36(4):270-275.
 11. **Claeys KC**, Weston LE, Pineles L, Morgan DJ, Krein SL. Implementing diagnostic stewardship to improve diagnosis of urinary tract infections across three medical centers: A qualitative assessment. *Infect Control Hosp Epidemiol*. 2023 Jul 10:1-10. Epub ahead of print. PMID: 37424224.
 12. Morgan DJ, Leekha S, **Claeys KC**. Increasing Evidence That Diagnostic Stewardship May Improve Antibiotic Use. *JAMA Intern Med*. 2023 July. Epub ahead of print
 13. Baghdadi JD, Goodman KE, Magder LS, Heil EL, **Claeys K**, Bork JT, Harris AD. Clinical, contextual, and hospital-level factors associated with escalation and de-escalation of empiric Gram-negative antibiotics among US inpatients. *JAC Antimicrob Resist*. 2023 May 13;5(3):dlad054. PMID: 37193004.
 14. Lapin JJ, Horback KM, Smith R, Johnson JK, **Claeys KC**. From Bottle to Bedside: Implementation Considerations and Antimicrobial Stewardship Considerations for Bloodstream Infection Rapid Diagnostic Testing. *Pharmacotherapy*. 2023 May 9. Epub ahead of print. PMID: 37158053
 15. **Claeys KC**, Johnson MD. Leveraging diagnostic stewardship within antimicrobial stewardship programmes. *Drugs Context*. 2023;12:2022-9-5. PMID: 36843619.
 16. McCrink KA, DeRonde KJ, Jimenez A, Rosello G, Natori Y, **Claeys KC**, Martinez OV, De Pascale B, Perez-Cardona A, Abbo LM, Vega AD. Impact of a Real-Time Diagnostic and Antimicrobial Stewardship

Workflow on Time-to-Appropriate Therapy for Infections Caused by Multidrug-Resistant Gram-negative Organisms. *Int J Antimicrob Agents*. 2023 Apr 8;106811 PMID: 37037319.

17. Heil EL, **Claeys KC**, Kline EG, Rogers TM, Squires KM, Iovleva A, Doi Y, Banoub M, Noval MM, Luethy PM, Shields RK. Early initiation of three-drug combinations for the treatment of carbapenem-resistant *A. baumannii* among COVID-19 patients. *J Antimicrob Chemother*. 2023 Apr 3;78(4):1034-1040. PMID: 36869724.
18. LaPlante R, **Claeys KC**, Bork JT, Banoub M, Noval M. Evaluating the Follow-up of Post-discharge Positive Sterile Site Cultures and the Impact on Infection-Related Complications. *Infect Dis Ther*. 2023 Mar;12(3):989-996. PMID: 36884212.
19. Advani SD, **Claeys KC**. Cefepime/Enmetazobactam for Complicated Urinary Tract Infections. *JAMA*. 2022 Oct 4;328(13):1299-1301. PMID: 36194235.
20. Zasowski EJ, Trinh TD, **Claeys KC**, Dryden M, Shlyapnikov S, Bassetti M, Carnelutti A, Khachatryan N, Kurup A, Pulido Cejudo A, Melo L, Cao B, Rybak MJ. International Validation of a Methicillin-Resistant *Staphylococcus aureus* Risk Assessment Tool for Skin and Soft Tissue Infections. *Infect Dis Ther*. 2022 Dec;11(6):2253-2263. PMID: 36319943.
21. Li C, **Claeys KC**, Justo JA, Heil EL. No Crystal Ball? Using Risk Factors and Scoring Systems to Predict Extended-Spectrum Beta-Lactamase Producing *Enterobacterales* (ESBL-E) and Carbapenem-Resistant *Enterobacterales* (CRE) Infections. *Curr Infect Dis Rep*. 2022 Oct 6; 24: 147 – 158.
22. Chang J, Patel D, Vega A, **Claeys KC**, Heil EL, Scheetz MH. Does calculation method matter for targeting vancomycin area under the curve? *J Antimicrob Chemother*. 2022 Jul 28;77(8):2245-2250. PMID: 35640658.
23. Kenea B, O'Hara N, O'Hara L, **Claeys KC**, Leekha S. Understanding healthcare provider preferences for ordering respiratory cultures to diagnose ventilator associated pneumonia: A discrete choice experiment. *Antimicrobial Stewardship & Healthcare Epidemiology*. 2022 2(1), E120. doi:10.1017/ash.2022.267
24. Goodman KE, Heil EL, **Claeys KC**, Banoub M, Bork JT. Real-World Antimicrobial Stewardship Experience in a Large Academic Medical Center: Using Statistical and Machine Learning Approaches to Identify Intervention “Hotspots” in an Antibiotic Audit and Feedback Program. *Open Forum Infect Dis*. 2022 Jun 10;9(7):ofac289.
25. Groft L, Mease J, Bernhardt C, Bork J, Johnson JK, **Claeys KC**. Follow-Up Blood Culture Practices for Gram-Negative Bloodstream Infections in Immunocompromised Hosts at a Large Academic Medical Center. *Open Forum Infect Dis*. 2022 Apr 15;9(5):ofac173. PMID: 35531383
26. Noval M, Leekha S, Armahizer M, Celotto A, Bhatt M, Seung H, **Claeys KC**. Evaluating the incidence of bacteriuria in female patients before and after implementation of external urinary collection devices. *Antimicrobial Stewardship & Healthcare Epidemiology*. 2022 2(1), E44. doi:10.1017/ash.2022.30
27. O'Hara NN, Carullo BS, Joshi M, Banoub M, **Claeys KC**, Sprague S, Slobogean GP, O'Toole RV. Does Cumulative Topical Antibiotic Powder Use Increase the Risk of Drug Induced Acute Kidney Injury in Fracture Patients? *Bone It Open*. 2022 Apr;3(4):284-290. PMID: 35363046
28. **Claeys KC**, Trautner BW, Leekha S, Coffey KC, Crnich CJ, Diekema D, Fakhri MG, Goetz MB, Gupta K, Jones MM, Leykum L, Liang SY, Pineles L, Pleiss A, Spivak ES, Suda KJ, Taylor J, Rhee C, Morgan DJ. Optimal Urine Culture Diagnostic Stewardship Practice— Results from an Expert Modified-Delphi Procedure. *Clin Infect Dis*. 2022 Aug 31;75(3):382-389.

29. Zasowski EJ, Trinh TD, **Claeys KC**, Lagnf AM, Bhatia S, Klinker KP, Veve MP, Estrada SJ, Johns ST, Sawyer AJ, Huang V, LaFrance B, Levine DP, Kaye KS, Davis SL, Rybak MJ. Multicenter Cohort Study of Ceftaroline versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection. *Open Forum Infect Dis*. 2022 Mar;9(3):ofab606. PMID: 35146040
30. Rock C, Perlmutter RF, Blythe D, Bork J, **Claeys K**, Cosgrove SE, Dzintars K, Fabre V, Harris AD, Heil EL, Hsu YJ, Keller S, Maragakis LL, Milstone AM, Morgan DJ, Dullabh P, Ubri S, Rotondo C, Brooks R, Leekha S. Impact of Statewide Prevention and Reduction of *Clostridioides difficile* (SPARC), a Maryland public health-academic collaborative: an evaluation of a quality improvement intervention. *BMJ Qual Saf*. 021 Dec 9:bmjqs-2021-014014. Epub ahead of print. PMID: 34887357
31. **Claeys KC**, Hopkins TL, Schlaffer K, Hitchcock S, Jiang Y, Evans S, Johnson JK, Leekha S. Comparing the clinical utility of rapid diagnostics for the treatment of Bloodstream Infections using Desirability of Outcome Ranking approach for the Management of Antibiotic Therapy (DOOR-MAT). *Antimicrob Agents Chemother*. 2021 Aug 17;65(9):e0044121. PMID: 34228533.
32. Howard AK, **Claeys K**, Biggs JM, Parbuoni KA, Johnson K, Luneburg P, Campbell J, Morgan JA. Performance of Verigene Rapid Diagnostic Testing for Detection of Inpatient Pediatric Bacteremia. *J Pediatr Pharmacol Ther*. 2021;26(5):472-477. PMID: 34239399.
33. Kruger-Howard A, Parbuoni KA, **Claeys K**, Biggs JM, Seung H, Johnson K, Campbell J, Morgan JA. Validation of neonatal and paediatric antimicrobial stewardship treatment algorithms in rapid diagnostic-detected bacteraemia. *Int J Pharm Pract*. 2021 Oct 18;29(5):486-492. PMID: 34173658.
34. Noval M, Heil EL, Williams P, Johnson JK, **Claeys KC**. The potential impact of discrepancies between automated susceptibility platforms and other testing methodologies for cefazolin in the treatment of *Enterobacteriales* bloodstream infections. *Diagn Microbiol Infect Dis*. 2021 Oct;101(2):115483. doi: 10.1016/j.diagmicrobio.2021.115483. PMID: 34339950.
35. Alosaimy S, Lagnf AM, Morrisette T, Scipione MR, Zhao JJ, Jorgensen SCJ, Mynatt R, Carlson TJ, Jo J, Garey KW, Allen D, DeRonde K, Vega AD, Abbo LM, Venugopalan V, Athans V, Saw S, **Claeys KC**, Miller M, Molina KC, Veve M, Kufel WD, Amaya L, Yost C, Ortwine J, Davis SL, Rybak MJ. Real-world, Multi-Center Experience with Meropenem-Vaborbactam for Gram-Negative Bacterial Infections including carbapenem-resistant *Enterobacteriales* and *Pseudomonas aeruginosa*. *Open Forum Infectious Diseases*. 2021 Jul 14;8(8):ofab371. PMID: 34430671.
36. Hart DE, Gallagher JC, Puzniak LA, Hirsch EB; C/T Alliance to deliver Real-world Evidence (CARE). A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients with Multidrug-Resistant *Pseudomonas aeruginosa* Infections. *Open Forum Infect Dis*. 2021 Mar 6;8(3):ofab089. doi: 10.1093/ofid/ofab089. PMID: 33796600.
37. **Claeys KC**, Schlaffer K, Smith R, Hitchcock S, Jiang Y, Evans SE, Johnson JK, Leekha S. Day at the Races: Comparing BioFire FilmArray Blood Culture ID Panels to Verigene Blood Culture in Gram-negative Bloodstream Infections using DOOR-MAT Analysis. *Clin Infect Dis*. 2021 Sep 15;73(6):1103-1106. doi: 10.1093/cid/ciab262. PMID: 33772269.
38. Sullivan KV, Gallagher JC, Leekha S, Morgan DJ, Morita K, Rock C, **Claeys KC**. Use of Diagnostic and Antimicrobial Stewardship Practices to Improve *Clostridioides difficile* Testing Among SHEA Research Network Hospitals. *Infect Control Hosp Epidemiol*. 2021 Aug 11:1-5. doi: 10.1017/ice.2021.133. Online ahead of print. PMID: 34376271.

39. Blackman AL, Ali S, Gao X, Mesumbe R, Cheung C, Banoub M, **Claeys KC**, Heil EL. Evaluation of Intra-Operative Topical Vancomycin and the Incidence of Acute Kidney Injury. *Surg Infect (Larchmt)*. 2021 Feb 10. Online ahead of print. PMID: 33571051.
40. Mody L, Akinboyo IC, Babcock HM, Bischoff WE, Cheng VC, Chiotos K, **Claeys KC**, Coffey KC, Diekema DJ, Donskey CJ, Ellingson KD, Gilmartin HM, Gohil SK, Harris AD, Keller SC, Klein EY, Krein SL, Kwon JH, Laurant AS, Livorsi DJ, Lofgren ET, Merrill K, Milstone A, Monsees EA, Morgan DJ, Perri LP, Pfeiffer CD, Rock C, Saint S, Sickbert-Bennett E, Skelton F, Suda KJ, Talbot TR, Vaughn VM, Weber DJ, Wiemken TL, Yassin MH, Ziegler MJ, Anderson DJ; SHEA Research Committee. COVID-19 Research Agenda for Healthcare Epidemiology. *Infect Control Hosp Epidemiol*. 2021 Jan 25:1-81. PMID: 33487199.
41. Barlow A, Heil EL, **Claeys KC**. Using an Ordinal Approach to Compare Outcomes Between Vancomycin Versus Ceftaroline or Daptomycin in MRSA Bloodstream Infection. *Infect Dis Ther*. 2021 Mar;10(1):605-612. PMID: 33484408.
42. Groft LM, **Claeys KC**, Heil EL. An evaluation of meropenem + vaborbactam for the treatment of nosocomial pneumonia. *Expert Opin Pharmacother*. 2021 Feb;22(3):265-271. PMID: 33090037.
43. **Claeys KC**, Zhan M, Pineles L, Lydecker A, Clore G, Goto M, Leekha S, Evans CT, Trautner BW, Goetz MB, Linkin D, Perencevich EN, Morgan DJ. Conditional reflex to urine culture: Evaluation of a diagnostic stewardship intervention within the Veterans' Affairs and Centers for Disease Control and Prevention Practice-Based Research Network. *Infect Control Hosp Epidemiol*. 2021 Feb;42(2):176-181. PMID: 32838829.
44. Bork JT, Leekha S, **Claeys K**, Seung H, Tripoli M, Amoroso A, Heil EL. Change in hospital antibiotic use and acquisition of multidrug-resistant gram-negative organisms after the onset of coronavirus disease 2019. *Infect Control Hosp Epidemiol*. 2020 Dec 10:1-3. PMID: 33298211.
45. **Claeys KC**, Morgan DJ, Leekha S, Sullivan KV. Diagnostic and antimicrobial stewardship with molecular respiratory testing across the SHEA Research Network. *Infect Control Hosp Epidemiol*. 2020 Dec 3;1-4. PMID: 33267918.
46. **Claeys KC**, Heil EL, Johnson JK, Leekha S. Management of Gram-Negative Bloodstream Infections in the Era of Rapid Diagnostic Testing: Impact with and Without Antibiotic Stewardship. *Open Forum Infect Dis*. 2020 Sep 12;7(10): ofaa427. PMID: 33134414.
47. **Claeys KC**, Heil EL, Brade KD. Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant Staphylococcus aureus Infection? Point/Counter Point – Pro. *Can J Hosp Pharm*. Oct 01; 73(4): 298.
48. Vega A, Heil EL, Blackman A, Banoub M, Johnson JK, Leekha S, **Claeys KC**. Reply to Letters to the Editor: Evaluation of the addition of IV metronidazole to PO vancomycin therapy in critically ill patients with non-fulminant, severe *C. difficile* infection. *Pharmacotherapy*. 2020 Sep;40(9):985-986. PMID: 33112455.
49. Vega AD, Jimenez A, Rossello G, **Claeys KC**, Martinez OV, De Pascale B, Perez-Cardona A, Abbo L. Implementing Carbapenem-resistance Testing Algorithms for *Enterobacteriaceae* and *Pseudomonas*: Diagnostic Antimicrobial Stewardship with timely Infection Prevention. *Diagn Microbiol Infect Dis*. 2020 Aug;97(4):115069. PMID: 32559587.
50. Bork JT, **Claeys KC**, Heil EL, Banoub M, Leekha S, Sorkin J, Kleinberg M. A Propensity Score Matched Study of the Positive Impact of Infectious Diseases Consultation on Antimicrobial Appropriateness in Hospitalized Patients with Antimicrobial Stewardship Oversight. *Antimicrob Agents Chemother*. 2020 Jul 22;64(8): e00307-20. PMID: 32423952.

51. Alosaimy S, Molina K, **Claeys KC**, Andrade J, Truong J, King MA, Pullinger BM, Huang G, Morrisette T, Lagnf AM, Rybak MJ. Early Experience with Eravacycline for Complicated Infections. *Open Forum Infect Dis*. 2020 Mar 2;7(5): ofaa071. PMID: 32411809.
52. Vega AD, Blackman AL, Banoub M, Heil EL, Leekha S, Johnson JK, **Claeys KC**. Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe *Clostridioides difficile* Infection. *Pharmacotherapy*. 2020 May;40(5):398-407. PMID: 32246501.
53. Smith JR, Rybak JM, **Claeys KC**. Imipenem-Relebactam: A β -lactamase Inhibitor Awakens. *Pharmacotherapy*. 2020 Apr;40(4):343-356. PMID: 32060929
54. Noval M, Banoub M, **Claeys KC**, Heil E. The Battle Is On: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms. *Curr Infect Dis Rep*. 2020 Jan 13;22(1):1. PMID: 31933158.
55. Lynch CS, Appleby-Sigler A, Bork JT, Davé R, Agnes K, Sanikop M, Heath D, Clark AF, **Claeys K**, Zhan M, Morgan DJ. Effect of Urine Reflex Culturing on Rates of Cultures and Infections in Acute and Long-Term Care. *Antimicrob Resist Infect Control*. 2020 Jun 29;9(1):96. PMID: 32600416.
56. Masich AM, Kalaria SN, Gonzales JP, Heil EL, Tata AL, **Claeys KC**, Patel D, Gopalakrishnan M. Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock. *Pharmacotherapy*. 2020 Mar;40(3):211-220. PMID: 31957057.
57. Fornaro R, Heil EL, **Claeys K**, Sheik HF, Zarowitz B, Brandt NJ. Identifying and Bridging the Gaps in Antimicrobial Stewardship in Post-Acute and Long-Term Care. *J Gerontol Nurs*. 2020 Jan 1;46(1):8-13. PMID: 31895956.
58. Jorgensen SC, Trinh TD, Zasowski EJ, Langf AM, Bhatia S, Melvin SM, Steed ME, Simon SP, Estrada SJ, Morrisette T, **Claeys KC**, Rosenberg JR, Davis SL, Rybak MJ. Real-world Experience with Ceftazidime-Avibactam for Multi-Drug Resistant Gram-Negative Infections. *Open Forum Infect Dis*. 2019 Dec 6;6(12): ofz522. PMID: 31890725.
59. Kenea B, Richert ME, **Claeys KC**, Shipper A, Sullivan KV, Schrank GM, O'Hara LM, Morgan DJ, Shanholtz C, Leekha S. Ventilator-Associated Pneumonia: Diagnostic Test Stewardship and Relevance of Culturing Practices. *Curr Infect Dis Rep*. 2019 Nov 21;21(12):50. PMID: 31754887.
60. Trinh TD, Jorgensen S, Zasowski EJ, **Claeys KC**, Lagnf AM, Estrada S, Delaportes D, Huang V, Klinker K, Kaye K, Davis SL, Rybak MJ. Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections. *Antimicrob Agents Chemother*. 2019 Oct 22;63(11). PMID: 31405859.
61. **Claeys KC**, Blanco-Herrera N, Morgan DJ, Leekha SL, Sullivan KV. Advances and Challenges in the Diagnosis and Treatment of Urinary Tract Infections: The Need for Diagnostic Stewardship. *Curr Infect Dis Rep*. 2019 Mar 5;21(4):11. PMID: 30834993.
62. **Claeys KC**, Zasowski EJ, Trihn TD, Casapao AM, Pogue JP, Myant RP, Wilson SS, Welch R, Levine DP, Kaye KS, Delgado G, Murray KP, Davis SL, Rybak MJ. Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant *Staphylococcus aureus*. *Infect Dis Ther*. 2019 Jun;8(2):199-208. PMID: 30915685.
63. **Claeys KC**, Hopkins TL, Brown SP, Heil EL. Perceptions of a transition to an AUC-guided pharmacist-to-dose vancomycin practice at a large academic medical center. *J Am Coll Clin Pharm*. 2019; 2:482-487.

64. [Gallagher JC](#), Molnar E, Satlin M, Elabor A, El-Beyrouty C, Heil E, **Claeys KC**, Dixit D, Hiles J, King M, Vyas N, Harrington N, Guo Y, Saraiya N. Ceftolozane-tazobactam for the treatment of multidrug-resistant *Pseudomonas aeruginosa* infections: A multicenter study. *Open Forum Infect Dis*. 2018 Oct 31;5(11). PMID: 30488041.
65. Heil EL, **Claeys KC**, Mynatt RP, Brade K, Hopkins TL, Rybak MJ, [Pogue JP](#). Making the change to area under the curve–based vancomycin dosing. *Am J Health Syst Pharm*. 2018 Dec 15;75(24):1986-1995. PMID: 30333114.
66. **Claeys KC**, Hopkins TL, Vega AD, [Heil EL](#). Fluoroquinolone Restriction as an Effective Antimicrobial Stewardship Intervention. *Curr Infect Dis Rep*. 2018 Mar 23; 20(5):7. PMID: 29572691.
67. **Claeys KC**, Zasowski EJ, Lagnf AM, Levine DP, Davis SL, [Rybak MJ](#). Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting. *Infect Dis Ther*. 2018 Dec;7(4):495-507. PMID: 30244362.
68. Vega AD, Heil EL, **Claeys K**, [Hynika L](#). Effectiveness of Eight Weeks of Ledipasvir/Sofosbuvir for Hepatitis C in HCV/HIV-co-infected Patients. *Antivir Ther*. 2018 Sep 7. PMID: 30192231.
69. **Claeys KC**, Schlaffer K, Heil EL, Leekha S, Johnson JK. Validation of an Antimicrobial Stewardship-Driven Verigene Blood-Culture Gram-Negative Treatment Algorithm to Improve Appropriateness of Antibiotics. *Open Forum Infect Dis*. 2018 Sep 15;5(10): ofy233. PMID: 30568975.
70. **Claeys KC**, Pogue JM, Heil EL, Lephart P, Johnson JK. The Verigene Dilemma: Gram-negative Polymicrobial Bloodstream Infections and Clinical Decision Making. *Diagn Microbiol Infect Dis*. 2018 Jun;91(2):144-146. PMID: 29449043.
71. [Pogue JM](#), Mynatt RP, Heil EL, Salimnia H, Johnson JK, **Claeys KC**. An Antibiotic Stewardship Program Blueprint for Optimizing Verigene BC-GN within an Institution: A Tale of Two Cities. *Antimicrob Agents Chemother*. 2018 Apr 26;62(5). PMID: 29483115.
72. Masich AM, Heavner MS, Gonzales JP, **Claeys KC**. Pharmacokinetic/Pharmacodynamic Considerations of Beta-Lactam Antibiotics in Adult Critically Ill Patients. *Curr Infect Dis Rep*. 2018 Apr 4; 20(5):9. PMID: 29619607.
73. Heavner MS, Masich AM, **Claeys KC**, [Gonzales JP](#). Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients. *Curr Infect Dis Rep*. 2018 Apr 5; 20(5):10. PMID: 29623443.
74. Trinh TD, Zasowski EJ, **Claeys KC**, Casapao AM, Compton M, Lagnf AM, Kidambi S, Levine DP, [Rybak MJ](#). Role of vancomycin minimum inhibitory concentrations by modified population analysis profile method in high inoculum methicillin-resistant *Staphylococcus aureus* infections. *Diagn Microbiol Infect Dis*. 2017 Sep;89(1):61-66. PMID: 29470836.
75. **Claeys KC**, Zasowski EJ, Trinh TD, Lagnf AM, Davis SL, [Rybak MJ](#). Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis. *Infect Dis Ther*. 2018 Mar;7(1):135-146. PMID: 29164489.
76. [Smith JR](#), Frens J, Smith C, Snider C, **Claeys KC**. Impact of a pharmacist-driven care package on *Staphylococcus aureus* bacteremia management in a large community healthcare network: A propensity score-matched, quasi-experimental study. *Diagn Microbiol Infect Dis*. 2018 Jan;90(1):50-54. PMID: 29153470.

77. **Claeys KC**, Zasowski EJ, Lagnf AM, Levine DP, Davis SL, Rybak MJ. Novel Application of Published Risk Factors for Methicillin-Resistant *S. aureus* in Acute Bacterial Skin and Skin Structure Infections. *Int J Antimicrob Agents*. 2018 Jan;51(1):43-46. PMID: 28668679.
78. Trinh TD, Zasowski EJ, **Claeys KC**, Lagnf AM, Kidambi S, Davis SL, Rybak MJ. Multidrug-resistant *Pseudomonas aeruginosa* lower respiratory tract infections in the intensive care unit: Prevalence and risk factors. *Diagn Microbiol Infect Dis*. 2017 Sep;89(1):61-66. PMID: 28716451.
79. Zasowski EJ, Trinh TD, **Claeys KC**, Casapao AM, Sabagha N, Lagnf AM, Klinker K, Davis SL, Rybak MJ. A Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. *Antimicrob Agents Chemother*. 2017 Jan 24;61(2). PMID: 27895012.
80. **Claeys KC**, Zasowski EJ, Lagnf AM, Nyguen CT, Nagel JL, Levine DP, Kaye KS, Davis SL, Rybak MJ. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant *Staphylococcus aureus* Bloodstream Infections. *Antimicrob Agents Chemother*. 2016 Sep 23;60(10):5841-8. PMID: 27431221.
81. **Claeys KC**, Lagnf AM, Hallesy JA, Compton MT, Gravelin AL, Davis SL, Rybak MJ. Pneumonia caused by methicillin-resistant *Staphylococcus aureus*: Does vancomycin heteroresistance matter? *Antimicrob Agents Chemother*. 2016 Jan 4; 60(3):1708-16. PMID: 26729497
82. Zasowski EJ, **Claeys KC**, Lagnf AM, Davis SL, Rybak MJ. Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infection. *Clin Infect Dis*. 2016 May 15;62(10):1242-1250. PMID 26945013
83. **Claeys KC**, Zasowski EJ, Lagnf AM, Rybak MJ. Comparison of outcomes between patients with single versus multiple positive blood cultures for Enterococcus: Infection or Illusion? *Am J Infect Control*. 2016 Aug 1;44(8):917-21. PMID: 26388037
84. **Claeys KC**, Lagnf AM, Patel TB, Jacob MG, Davis DL, Rybak MJ. Acute bacterial skin and skin structure infections treated with intravenous antibiotics in the emergency department or observational unit: Experience at the Detroit Medical Center. *Infect Dis Ther*. 2015 Jun;4(2):173-86. PMID: 26055392
85. Casapao AM, Lodise TP, Davis SL, **Claeys KC**, Kullar R, Levine DP, Rybak MJ. Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant *Staphylococcus aureus* infective endocarditis. *Antimicrob Agents Chemother*. 2015 Jun; 59(6): 2978-85. PMID: 25753631
86. **Claeys KC**, Smith JR, Casapao AM, Mynatt RP, Avery L, Schroff A, Yamamura D, Davis SL, Rybak MJ. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant *Staphylococcus aureus* infections. *Antimicrob Agents Chemother*. 2015 Apr; 59(4): 1969-76. PMID: 25605354
87. **Claeys KC**, Fiorvento AD, Rybak MJ. A review of novel combinations of colistin and lipopeptide or glycopeptide antibiotics for the treatment of multidrug-resistant *Acinetobacter baumannii*. *Infect Dis Ther*. 2014; 3:69–81. PMID: 25475412
88. Smith JR, **Claeys KC**, Barber KE, Rybak MJ. High dose daptomycin therapy for staphylococcal endocarditis and when to apply it. *Curr Infect Dis Rep*. 2014 Oct; 16(10): 429. PMID: 2516501

NON-PEER-REVIEWED PUBLICATIONS

1. **Claeys KC**, Fong K. Keeping Updated on Clinical Rapid Diagnostic Tests for Bacteremia and Beyond. *Infectious Diseases Special Edition*. <https://www.idse.net/> September 2023
2. **Claeys KC**, Noval MN. Diagnostic Stewardship to Augment Antimicrobial Stewardship Activities Beyond the Management of Bloodstream Infections. *Contagion Magazine* February 2019
3. **Claeys, KC**. Guidance on How to Measure the Effectiveness of Incorporating Antibigram Data at Your Facility. *AMDA: The Society of Post-Acute and Long-Term Care Medicine* December 2019
4. **Claeys KC**, Morgan DJ, Leekha S. Applying Stewardship Principles to Decrease Unnecessary Urine Culturing. Maryland Department of Health Office of Antibiotic Resistance & Healthcare Associated Infection Response Newsletter Maryland Department of Health June 2019
5. **Claeys KC**. Multivariable logistic regression primer for clinicians. *Maryland Health-Systems Pharmacists Pharmascript* April 2018
6. Morrisette T, **Claeys KC**. Five Things to Know About Combination Therapy with Daptomycin Plus Ceftaroline for The Treatment of *Staphylococcus aureus* Bacteremia. *ID Stewardship* www.idstewardship.com March 2018
7. **Claeys KC**. Understanding sensitivity, specificity, positive, and negative predictive value. *Maryland Health-Systems Pharmacists Pharmascript* October 2017
8. Smith JR, **Claeys KC**. Cefiderocol: A 21st Century Trojan Horse. *Society of Infectious Disease Pharmacists Newsletter* October 2017
9. **Claeys KC**. Using the p value to interpret significant results – not the be-all end-all. *Maryland Health-Systems Pharmacists Pharmascript* April 2017
10. Vega AD, Baily J, **Claeys KC**. Advancements in the management of *C. difficile* infections. *MAD-ID Newsletter* April 2017 (ACPE No. 0485-000-17-019-H01-P)
11. **Claeys KC**. MRSA Bloodstream Infection: Daptomycin, Vancomycin Or Other? *ID Stewardship* www.idstewardship.com April 2017
12. Rybak JM, **Claeys KC**. Isavuconazole, a new agent for the treatment of invasive mold infections. *MAD-ID Newsletter* June 2015 (ACPE No. 0485-0000-15-018-H01-P)
13. **Claeys KC**, Dodd P. New and notable medications approved in 2010 and 2011. *Michigan Pharmacist Journal* June 2011 (ACPE No. 112-000-11-009-H01-P)

TEXTBOOK CHAPTERS

1. **Claeys KC**, Morgan DJ Coffey KC. (2021) Diagnostic Stewardship. In Bearman G, Munoz-Price S, Morgan DJ, Murthy KR (Eds). *Infection Prevention: New Perspectives and Controversies*, Second Edition. New York, NY, Springer.
2. **Claeys KC**, Blanco N, Leekha S. (2021) The Importance of *C. difficile* Colonization in Infection Prevention. In Bearman G, Munoz-Price S, Morgan DJ, Murthy KR (Eds). *Infection Prevention: New Perspectives and Controversies*, Second Edition. New York, NY, Springer.
3. Smith JR, **Claeys KC**, Zasowski EJ, Yim J, Rybak MJ (2017). Daptomycin Resistance. In Kaye KS, Mayers DL, Sobel JD, et al. (Eds.) *Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, Volume 1* (pp. 307 - 17). New York, NY, Springer.

RESEARCH POSTERS & PLATFORMS

1. Moon R, MacVan S, Morton J, David J, Rosenthal N, **Claeys KC**. Clinical outcomes of receiving early phenotype-directed antimicrobial therapy among hospitalized patients with Enterobacterales bloodstream infection in the United States. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, April 2024 [oral presentation].
2. Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Cifuentes R, **Claeys KC**, DeSear K, Gallagher JC, Gregory E, Heil EL, Hickey C, Klatt M, Kline EG, Kubat RC, Kufel WD, Hyoung Lee J, Lim A, Lingg T, MacDougall C, Mathers A, McCreary EK, Moore WJ, Olson S, Oxer J, Pearson JC, Pham C, Polk C, Satlin MJ, Satola SW, Shah S, Solanki YB, Tamma P, Vega A, Veena V, Veve M, Wangchinda W, Witt LS, Wu JM, Pogue. Time to clinical response among patients treated with ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant *Pseudomonas aeruginosa* infections in the United States (CACTUS). European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, April 2024 [oral presentation].
3. Shields RK, Abbo LM, Ackley R, Aitken SL, Albrecht B, Babiker A, Cifuentes R, **Claeys KC**, DeSear K, Gallagher JC, Gregory E, Heil EL, Hickey C, Klatt M, Kline EG, Kubat RC, Kufel WD, Hyoung Lee J, Lim A, Lingg T, MacDougall C, Mathers A, McCreary EK, Moore WJ, Olson S, Oxer J, Pearson JC, Pham C, Polk C, Satlin MJ, Satola SW, Shah S, Solanki YB, Tamma P, Vega A, Veena V, Veve M, Wangchinda W, Witt LS, Wu J, Pogue jason M. 2023. 1109. A multicenter, observational study to compare the effectiveness of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam for multidrug-resistant *Pseudomonas aeruginosa* infections in the United States (CACTUS). IDWeek 2023, Boston MA, October 2023 [poster]
4. Lapin JJ, Gogineni A, Singh K, Goa N, Johnson JK, **Claeys KC**. Evaluation of the Impact of Polymicrobial Bloodstream Infections (BSIs) on the Performance of BioFire Blood Culture Identification 2 (BCID2) Multiplex Polymerase Chain Reaction (PCR) Panel. IDWeek 2023, Boston MA, October 2023 [poster]
5. Li C, Tadesse Y, Coffey KC, Morgan DM, **Claeys KC**. Evaluation of Optimal Urinalysis Criteria for Conditional Urine Culturing. IDWeek 2022, Washington DC, October 2022 [poster]
6. Tripathi R, Kenaa B, **Claeys KC**, Patel M, Maldarelli M, Newman M, Leekha S. Evaluating Respiratory Tract Culturing in Mechanically Ventilated Patients: Opportunity for Diagnostic Stewardship. IDWeek 2022, Washington DC, October 2022 [poster]
7. LaPlante R, **Claeys KC**, Bork JT, Banoub M, Noval M, Evaluating the prevalence of follow-up on post-discharge positive bacterial culture results from sterile site cultures and impact on infection-related complications. IDWeek 2022, Washington DC, October 2022 [poster]

8. Kunz Coyne AJ, Alosaimy S, Molina KC, Kang-Birken L, Lagnf AM, **Claeys KC**, et al. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints. IDWeek 2022, Washington DC, October 2022 [poster]
9. **Claeys KC**, Zou I, Abate D, Heil EL, Leekha S. Crossroads of antimicrobial and diagnostic stewardship: clinical decision support to optimise time to effective therapy against multidrug-resistant *Pseudomonas aeruginosa*. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Lisbon, Portugal, April 2022 [oral poster presentation]
10. Heil EL, **Claeys KC**, Kline EG, Rogers TM, Banoub M, Noval M, Luethy P, Shields RK. Utility of Three-Drug Combinations for the Treatment of Carbapenem-Resistant *Acinetobacter baumannii* Infections Among COVID-19 Patients. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Lisbon, Portugal, April 2022 [oral poster presentation]
11. Alosaimy S, Molina K, **Claeys KC**, Bouchard J, Andrade J, Troung J, King M, Pullinger B, Haung G, Morrisette T, Lagnf AM, Davis SL, Rybak MJ. Evaluation of Predictors for Clinical Success in Patients Treated with Eravacycline for Various Infections. IDWeek [Virtual Conference], October 2021 [poster]
12. Groft LM, Mease J, Bernhardt C, Bork J, **Claeys KC**. Follow-Up Blood Culture Practices for Gram-Negative Bloodstream Infections in Immunocompromised Hosts at a Large Academic Medical Center. IDWeek [Virtual Conference], October 2021 [oral platform presentation]
13. Groft LM, Opran O, Tadesse Y, Vo H, Heil EL, Shrank G, **Claeys KC**. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19. IDWeek [Virtual Conference], October 2021 [poster]
14. Groft LM, Noval M, Mease J, Johnson JK, **Claeys KC**. Using DOOR-MAT to Theoretically Compare Three Rapid Diagnostic Tests for Gram-Negative Bloodstream Infections in Immunocompromised Patients. IDWeek [Virtual Conference], October 2021 [poster]
15. Heil EL, **Claeys KC**, Luethy PM. Is MIC all that matters? MIC Distributions of Ceftazidime and Cefepime in Ceftriaxone-Resistant *E. coli* and *Klebsiella* spp. IDWeek [Virtual Conference], October 2021 [poster]
16. J Chang, Patel D, **KC Claeys**, Scheetz M, Heil EH. Does calculation method matter for targeting vancomycin AUC? IDWeek [Virtual Conference], October 2021 [poster]
17. Rebold N, Alosaimy S, Lagnf AM, Ansari I, Belza AC, Cheaney L, Hussain H, Herbin S, Morrisette T, Abdul-Mutakabbir J, Carron C, Holger D, **Claeys KC**, Davis SL, Ramesh M, McKinnon JE, Sandhu J, Chopra T, Rybak MJ. Evaluation of positive blood cultures on patient outcomes with COVID-19. European Congress of Clinical Microbiology and Infectious Disease (ECCMID) [Virtual Conference], June 2021 [poster]
18. JT Bork, S Leekha, **KC Claeys**, H Seung, M Tripoli, A Amoroso, E Heil. Change in Hospital Antibiotic Use and Acquisition of Multidrug Resistant Gram-Negative Organisms After Onset of Coronavirus Disease 2019. ESCMID Conference on Coronavirus Disease [Virtual Conference], September 2020 [poster]
19. Noval M, Bhatt M, Colletto A, Armahizer M, Leekha S, **Claeys KC**. Evaluating the incidence of bacteriuria in female patients before and after implementation of external catheter devices. IDWeek [Virtual Conference], October 2020 [poster]
20. Noval M, Heil EL, Willaims P, Johnson JK, **Claeys KC**. Comparison of cefazolin susceptibilities of Enterobacterales with an automated susceptibility testing platform versus in vitro antimicrobial testing. IDWeek [Virtual Conference], October 2020 [poster]

21. **Claeys KC**, Smith RD, Leekha S, Johnson JK. Comparison of Molecular Rapid Diagnostic Testing Panels for Gram-negative Bacteremia using Desirability of Outcome Ranking Management of Antimicrobial Therapy (DOOR-MAT). European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [poster]
22. **Claeys KC**, Heil EL, Johnson JK, Leekha L. Comparing Clinical Outcomes in Gram-negative Bloodstream Infections with Desirability of Outcomes Ranking: Focus on Non-Fermenting Organisms. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [poster]
23. Bork J, **Claeys KC**, Heil EL, Banoub M, Leekha S, Sorkin J, Kleinberg M. The Positive Impact of Infectious Diseases Consultation on Antimicrobial Appropriateness in Hospitalized Patients with Antimicrobial Stewardship Oversight: A propensity-score matched study. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [oral platform]
24. Alosaimy S, Molina K, **Claeys KC**, Andrade J, Troung J, King M, Pullinger B, Haung G, Morrisette T, Lagnf AM, Rybak MJ. Real-World Multicenter Experience with Eravacycline at Academic Hospital Systems. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [poster]
25. Alosaimy S, Lagnf AM, Jorgensen S, Morrisette T, Carlson T, Jo J, Garey K, Allen D, Venugopalan V, Davis SL, Veve M, **Claeys KC**, Athans V, Saw S, Ortwine J, Yost, Mynatt R, Pogue J, Rybak MJ. Real-World Multicenter Experience of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [poster]
26. Smith RD, Hitchcock S, Johnson JK, **Claeys KC**. Comparison of Three Rapid Diagnostic Blood Culture Identification Panels for Gram-Negative Bloodstream Infections. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [poster]
27. McCrink KA, DeRonde KJ, Jimenez A, Rosello G, Natori Y, **Claeys KC**, Martinez OV, DePascale B, Perez-Cardona A, Abbo L, Vega AD. Impact of Diagnostic and Antimicrobial Stewardship on Time-to-Appropriate Therapy and Clinical Outcomes in Infections caused by Carbapenem-resistant Gram-negative Organisms. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2020, Paris, France [mini oral session]
28. Rock C, Perlmutter RF, Blythe D, Bork J, **Claeys KC**, Cosgrove SE, Dzintars K, Fabre V, Harris AD, Heil EL, Hsu YJ, Keller S, Maragakis LL, Milstrone AM, Morgan DJ, Brooks R, Leekha S. SPARC (Statewide Prevention and Reduction of Clostridioides difficile) collaborative; a unique Maryland public health-academic medicine partnership reduced CDI across the state. Society of Healthcare Epidemiology or America Decennial Meeting 2019, Atlanta, GA [Poster]
29. Howard AK, **Claeys KC**, Parbuoni K, Biggs J, Johnson JK, Luneburg P, Campbell J, Morgan JA. Comparative effectiveness of pediatric and neonatal antimicrobial stewardship treatment algorithms in rapid diagnostic-detected bacteremia. ACCP Global Conference on Clinical Pharmacy, October 2019, New York, NYC [Poster]
30. Blackman AL, Ali S, Gao X, Mesumbe R, Cheung C, Banoub M, **Claeys KC**, Heil EL. Evaluation of intraoperative topical vancomycin and the incidence of acute kidney injury. IDWeek, October 2019, Washington, DC [Poster]
31. Vega AD, Blackman AL, Banoub M, Heil EL, Leekha S, Johnson JK, **Claeys KC**. No Mortality Benefit to Adding Intravenous Metronidazole to Oral Vancomycin for Critically ill Patients with Severe C. difficile Infection. IDWeek, October 2019, Washington, DC [Poster]

32. **Claeys KC**, Heil EL, Loughry N, Chainani S, Johnson JK, Leekha S. Use of Rapid Diagnostic Testing in Gram-negative Bloodstream Infections with and without Antimicrobial Stewardship. IDWeek, October 2019, Washington, DC[Poster]
33. **Claeys KC**, Schlaffer KS, Kpadeh-Rogers Z, Evans SR, Jiang Y, Johnson JK, Leekha S. Comparing the Clinical Utility of Rapid Diagnostic Tests for Gram-negative Bloodstream Infection using a Desirability of Outcomes Ranking. IDWeek, October 2019, Washington, DC[Poster]
34. **Claeys KC**, Hopkins TL, Kpadeh-Rogers Z, Evans SR, Jiang Y, Johnson JK, Leekha S. Comparison of Rapid Diagnostic Tests for Bloodstream Infections using Desirability of Outcome Ranking Management of Antimicrobial Therapy (DOOR-MAT). IDWeek, October 2019, Washington, DC[Poster]
35. Lynch CS, **Claeys KC**, Appleby-Sigler A, Bork JT, Davé R, Agnes J, Clark AD, Morgan DJ. Effect of Reflex Urine Culturing on Rates of Cultures and Infections in an Acute Care Hospital, Emergency Department, and Two Long-Term Care Facilities. IDWeek, October 2019, Washington, DC[Poster]
36. Johnson JK, Kpadeh-Rogers Z, Paszkiewicz G, **Claeys KC**. Comparison of the Verigene® and the ePlex® Blood Culture Identification Panels for Gram-Positive and Gram-Negative Bloodstream Infections. IDWeek, October 2019, Washington, DC[Poster]
37. Bork JT, **Claeys KC**, Johnson JK, Obiekwe U, Lusby M, Jones J, Heil EL, Leekha S. Back to the Future: The Impact of Multi-step Algorithm *C. difficile* Testing at a Large Tertiary Medical Center. IDWeek, October 2019, Washington, DC[Poster]
38. Ali S, **Claeys KC**. Derivation of a Prediction Model for Risk of Drug-Resistant Urinary Tract Infection. IDWeek, October 2019, Washington, DC[Poster]
39. Masich A, Kalaria S, Gonzales J, Heil E, Tata A, **Claeys KC**, Patel D, Gopalakrishnan M. Comparison of Vancomycin Trough Attainment in Obese Septic Patients Versus Non-Obese Septic Patients. Society of Critical Care Medicine (SCCM), February 2019, San Diego, CA [Platform]
40. Masich A, Kalaria S, Gonzales J, Heil E, Tata A, **Claeys KC**, Patel D, Gopalakrishnan M. Characterization of vancomycin pharmacokinetics and pharmacodynamics in obese septic shock patients. ACCP Global Conference on Clinical Pharmacy, October 2018, Seattle, WA [Poster]
41. **Claeys KC**, Hopkins TL, Heil EL. Perceptions of a transition to an AUC-guided pharmacist-to-dose vancomycin practice at a large academic medical center. ACCP Global Conference on Clinical Pharmacy, October 2018, Seattle, WA [Poster]
42. **Claeys KC**, Callahan P, Vega AD, Heil EL. Impact of an AUC-guided versus trough-guided vancomycin dosing strategy. ACCP Global Conference on Clinical Pharmacy, October 2018, Seattle, WA [Poster]
43. Vega AD, Nguyen C, **Claeys KC**, Heil EL. Characterizing variability in calculated vancomycin pharmacokinetic parameters using an AUC-based dosing strategy in hospitalized patients. ACCP Global Conference on Clinical Pharmacy, October 2018, Seattle, WA [Poster]
44. Zasowski EJ, Trinh TD, **Claeys KC**, Dryden M, Shlyapnikov S, Bassetti M, Carnelutti A, Khachatryan N, Kurup A, Pulido Cejudo A, Henrique Melo L Cao B, Rybak MJ. International validation of a Methicillin-Resistant *Staphylococcus aureus* (MRSA) risk assessment tool for acute bacterial skin and skin structure infections (ABSSSI). IDWeek, October 2018, San Francisco, CA [Poster]

45. Vega AD, Hopkins TL, Heil EL, Johnson JK, Leekha S, **Claeys KC**. Oral vancomycin plus intravenous metronidazole for severe *Clostridium difficile* infection in critically ill patients. IDWeek, October 2018, San Francisco, CA [Poster]
46. **Claeys KC**, Loughry N, Chainani S, Leekha S, Heil EL. Oral antibiotics for the treatment of Gram-negative bloodstream infections: Prescribing practices and outcomes at a large academic medical center. IDWeek, October 2018, San Francisco, CA [Poster]
47. Johnson N, Mattingly TJ, Johnson JK, **Claeys, KC**. Review of VERIGENE blood culture errors and discrepancies reported at a large academic medical centre. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2018, Madrid, Spain [Poster]
48. Nguyen C, Heil EL, **Claeys KC**. Can previously published literature combined with a small institution-specific data-set aid in the prediction of drug resistance in pneumonia presenting from the community? European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2018, Madrid, Spain [Poster]
49. Johnson JK, **Claeys KC**, Heavner M, Jani N, Leekha S. The first KPC-producing *Acinetobacter baumannii* complex in continental USA. Infections. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2018, Madrid, Spain [Poster]
50. AM Lagnf, SC Jorgensen, EJ Zasowski, TD Trinh, **KC Claeys**, KP Klinker, SJ Estrada, SL Davis, V Huang, BA Potoski, DP Levine, KS Kaye, MJ Rybak. A retrospective analysis of clinical outcomes in patients treated with vancomycin or daptomycin or ceftaroline for Methicillin-Resistant *Staphylococcus aureus* bloodstream infections. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2018, Madrid, Spain [Poster]
51. Molnar EM, Heil EL, **Claeys KC**, Hiles J, Gallagher JC. Ceftolozane-tazobactam for the treatment of multi drug resistant *Pseudomonas aeruginosa* (MDRPA) infections: A multicenter study. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2018, Madrid, Spain [Poster]
52. Hanretty A, Bia T, **Claeys KC**, King M, Peahota M, Gallagher JC. Comparison of acute kidney injury of beta-lactam/beta-lactamase inhibitor combinations compared to polymyxins in the treatment of multidrug-resistant Gram-negative infections. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2018, Madrid, Spain [Poster]
53. Masich AM, Kalaria SN, Gonzales JP, Heil EL, Tata AL, **Claeys KC**, Patel D, Gopalakrishnan M. Characterization of vancomycin pharmacokinetics and pharmacodynamics in obese septic patients with Gram-Positive bacteremia. ACCP Global Conference on Clinical Pharmacy, October 2017, Tucson, AZ [Poster]
54. **Claeys, KC**, Pogue JP, Lephart P, Heil EL, Johnson JK. Gram-Negative polymicrobial bloodstream infections and clinical decision making with a microarray testing system. IDWeek, October 2017, San Diego, CA [Poster]
55. Schlaffer K, Heil EL, Leekha S, Johnson JK, **Claeys KC**. Validation of an antimicrobial stewardship driven Verigene® blood-culture gram-negative treatment algorithm to improve appropriateness of antibiotics. IDWeek, October 2017, San Diego, CA [Poster]
56. Heil EL, Sivasailam B, Park S, Diaz J, von Rosenvinge E, **Claeys KC**, Hopkins TL, Leekha S. Impact of a multi-disciplinary *C. difficile* action team. IDWeek, October 2017, San Diego, CA [Poster]

57. Vega AD, Hynick L, **Claeys KC**, Heil EL. Effectiveness of 8- or 12-week treatment duration of Ledipasvir/Sofosbuvir for Hepatitis C: Evidence from a large academic medical center. IDWeek, October 2017, San Diego, CA [Poster]
58. Molnar EM, Heil EL, **Claeys KC**, Hiles J, Gallagher JC. Ceftolozane-tazobactam for the Treatment of Multi Drug Resistant Pseudomonas aeruginosa (MDRPA) Infections. IDWeek, October 2017, San Diego, CA [Poster]
59. Zasowski EJ, Trinh TD, **Claeys KC**, Lagnf AM, Delaportas D, Estrada SJ, Davis SL, Klinker KP, Huang V, Potoski BA, Levine DP, Kaye KS, Bonine NG, Gillard P, Rybak MJ. Clinical and economic comparison of Ceftaroline Fosamil (CPT) and Daptomycin (DAP) for Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI). IDWeek, October 2017, San Diego, CA [Poster]
60. Trinh TD, Zasowski EJ, **Claeys KC**, Lagnf AM, Delaportas D, Estrada SJ, Davis SL, Klinker KP, Huang V, Kaye KS, Bonine NG, Gillard P, Rybak MJ. Ceftaroline Fosamil (CPT) versus vancomycin (VAN) for acute bacterial skin and skin structure infections (ABSSSI). IDWeek, October 2017, San Diego, CA [Poster]
61. Zasowski EJ, Trinh TD, **Claeys KC**, Lagnf AM, Sabagha N, Sherwin RL, Welch RD, Rybak MJ. Clinical characteristics of patients with skin and soft tissue infections (SSTI) presenting to the emergency department: A focus on Methicillin-Resistant Staphylococcus aureus (MRSA) risk and antibiotic prescribing. ASM Microbe, June 2017, New Orleans, LA [Poster]
62. **Claeys KC**, Heil EL, Johnson JK, Lephart P, Mynatt RP, Salimnia H, Pogue JM. An antibiotic stewardship programme (ASP) blueprint for optimizing Verigene BC-GN within an institution: a tale of two cities. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2017, Vienna, Austria [Poster]
63. Trinh TD, Zasowski EJ, **Claeys KC**, Dryden M, Shlyapnikov S, Bassetti M, Cernelutti A, Khachatryan N, Kurup A, Cejudo A, Melo L, Cao B, Rybak MJ. International validation of a risk-assessment tool for Methicillin-Resistant Staphylococcus aureus acute bacterial skin and skin-structure infections. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2017, Vienna, Austria [Poster]
64. Smith JR, Frens J, Smith C, Snider C, **Claeys KC**. Effects of a Staphylococcus aureus bacteremia care package intervention on patient care in a community teaching hospital: A propensity-score matched comparison. IDWeek, October 2016, New Orleans, LA [Poster]
65. **Claeys KC**, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Use of Intravenous versus oral antibiotics in the emergency department/observation unit (ED/OU) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). ASM Microbe, June 2016, Boston, MA [Poster]
66. Trinh TD, Zasowski EJ, **Claeys KC**, Lagnf AM, Davis SL, Rybak MJ. Predictors of multidrug resistant (MDR) Pseudomonas aeruginosa nosocomial pneumonia in the intensive care unit (ICU). ASM Microbe, June 2016, Boston, MA [Poster]
67. **Claeys KC**, Levine DP. Length of bacteraemia and mortality in S. aureus infective endocarditis. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2016, Amsterdam, Netherlands [E-Poster]
68. Zasowski EJ, Trinh TD, **Claeys KC**, Lagnf AM, Casapao AM, Davis SL, Rybak MJ. Relationship between duration of methicillin-resistant Staphylococcus aureus bloodstream infection and mortality. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2016, Amsterdam, Netherlands [Poster]

69. Zasowski EJ, Trinh TD, **Claeys KC**, Lagnf AM, Casapao AM, Davis SL, Rybak MJ. Ceftaroline Fosamil for the treatment of methicillin-resistant *Staphylococcus aureus* infective endocarditis. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2016, Amsterdam, Netherlands [E-Poster]
70. **Claeys KC**, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Burden of illness with Gram-negative (GN) lower respiratory infections (LRTIs) admitted to intensive care units (ICUs). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Poster]
71. **Claeys KC**, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Risk Assessment and severity analysis in acute bacterial skin and skin structure infections (ABSSSIs). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Poster]
72. Zasowski EJ, **Claeys KC**, Casapao AM, Sabagha N, Klinker KP, Davis SL, Rybak MJ. Ceftaroline fosamil (CPT) for the treatment of methicillin-resistant *Staphylococcus aureus* pneumonia. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Poster]
73. Zasowski EJ, **Claeys KC**, Casapao AM, Sabagha N, Klinker KP, Davis SL, Rybak MJ. Ceftaroline fosamil (CPT) for the treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) bloodstream infections (BSI). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Poster]
74. **Claeys KC**, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Practical application of risk factors for methicillin-resistant *Staphylococcus aureus* (MRSA) in the treatment of antibacterial skin and skin structure infections (ABSSSI). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Platform]
75. **Claeys KC**, Zasowski EJ, Lagnf AM, Davis SL, DP Levine, KS Kaye, Rybak MJ. Propensity Matched analysis of daptomycin versus vancomycin for bloodstream infections caused by methicillin-resistant *Staphylococcus aureus* (MRSA). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Platform]
76. Zasowski EJ, **Claeys KC**, Lagnf AM, Witt JS, Rybak MJ. Predictors of vancomycin-resistant enterococci among patients with community-onset enterococcal bloodstream infections. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Platform]
77. Zasowski EJ, **Claeys KC**, Lagnf AM, Witt JS, Rybak MJ. Linezolid versus high-dose daptomycin for the treatment of vancomycin-resistant enterococcus bloodstream infections. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2015, San Diego, CA [Platform]
78. **Claeys KC**, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Burden of illness associated with acute bacterial skin and skin structure infections evaluated in the emergency department (ED) or observation unit (OU): Experience at the Detroit Medical Center. Making a Difference in Infectious Disease (MAD-ID), May 2015, Orlando, FL [Poster]
79. **Claeys KC**, Lagnf AM, Gravelin A, Hallesy J, Alderson R, Davis SL, Rybak MJ. Clinical outcomes of patients with heterogeneous vancomycin-intermediate *S. aureus* (hVISA) lower respiratory tract infections. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2015, Copenhagen, Denmark [Poster]
80. **Claeys KC**, Lagnf AM, Rybak MJ. Length of enterococcal bacteremia and associated clinical outcomes. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2015, Copenhagen, Denmark [Poster]

81. **Claeys KC**, Casapao AM, Davis DL, Rybak MJ. Burden of illness associated with acute bacterial skin and skin structure infections evaluated in the emergency department or observational unit: Experience at the Detroit Medical Center. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2014, Washington, DC [Poster]
82. **Claeys KC**, Nagel JL, Pogue JM, Casapao AM, Finks K, Neuhauser M, Schneider A, Davis SL, and Rybak MJ. Implementing the National Healthcare Safety Network's (NHSN's) Antimicrobial Use Option to aid in determination of resistance among key nosocomial pathogens. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2014, Washington, DC [Poster]
83. Nagel JL, Pogue JM, **Claeys KC**, Casapao AM, Finks J, Rybak MJ. Utilization of the Centers for Disease Control and Prevention National Healthcare Safety Network Antimicrobial Use and Resistance Module (CDC AUR) to compare multicenter antimicrobial use. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), October 2014, Washington, DC [Poster]
84. **Claeys KC**, Casapao AM, Pogue J, Bhatia N, Mynatt RP, Saely S, Arthur C, Welch R, Sherwin R, Hafeez W, Levine D, Kaye K, Delgado G, Giuliano CA, Talka R, Johnson LB, Davis SL, Rybak MJ. Rapid diagnostic testing with GeneXpert improves enrollment in a randomized clinical trial for detection of methicillin-resistant *S. aureus* in acute bacterial skin and skin structure infections. European Congress of Clinical Microbiology and Infectious Disease (ECCMID), April 2014, Barcelona, Spain [Poster]

NATIONAL & INTERNATIONAL PRESENTATIONS

Diagnostic Stewardship for Ventilator Associated Pneumonia: Pilot Study Centers for Disease Control and Prevention (CDC) Epicenters, online	10/2023
Diagnostic Stewardship as a Nudge to Decrease Inappropriate Treatment of Urine Cultures Veteran's Affairs (VA) Hospital Kicking CA-UTI National Initiative, online	10/2023
Optimizing Diagnostic Stewardship within Antimicrobial Stewardship Programs ID Grand Rounds, The Texas Medical Center, Houston, TX	07/2023
Engaging Pharmacists in Diagnostic Excellence National Academy of Medicine, Washington DC	06/2023
Optimizing Diagnostic Stewardship to Reduce Antibiotic Use SHEA Spring Meeting, Seattle, Washington	04/2023
Stewardship Educational Webinar: Diagnostic Stewardship The Veteran's Affairs (VA) Antimicrobial Stewardship Task Force, online	03/2023
Antimicrobial Stewardship for Outpatient and Emergency Department Settings Virginia Infection Prevention Treatment Center (VIPTC), Virginia Department of Health, online	03/2023
Diagnostic & Antimicrobial Stewardship Experience Optimizing RDTs for the Management of Bacteremia Medical Education for bioMérieux Canada, Inc., online	01/2023

Leveraging the BIOFIRE® Blood Culture Identification 2 (BCID2) panel for diagnostic and antimicrobial stewardship IDWeek Learning Lounge, Washington, DC	10/2022
Diagnostic Stewardship for Common Syndromes [moderator] IDWeek, Washington, DC	10/2022
Assessing the Potential Clinical, Public Health, and Economic Benefits of Bacterial Diagnosis Duke Margolis Center for Health Policy, Advancing Bacterial Diagnostic Coverage, Reimbursement, and Utilization, Washington, DC	06/2022
Meet the Professors Making a Difference in Infectious Diseases (MAD-ID), Orlando, FL	05/2022
These are Exciting Times: Implementing Diagnostic Stewardship into Traditional Antimicrobial Stewardship Programs Making a Difference in Infectious Diseases (MAD-ID), Orlando, FL	05/2022
Leveraging Diagnostics for Stewardship in Common Infections Duke Antimicrobial Stewardship Outreach Network (DASON), online	02/2022
Exploring diagnostic and antimicrobial stewardship interventions to optimize management of gram-negative bacteremia College of American Pathologists (CAP) Today, online webinar	12/2021
Comparing the utility of rapid diagnostics for the treatment of bloodstream infections using DOOR-MAT Society of Infectious Diseases Pharmacists (SIDP) Annual Meeting, online	11/2020
Expert updates in gram-negative resistance Society of Infectious Diseases Pharmacists (SIDP) Education Center Webinar, online	06/2020
Combining laboratory and antimicrobial stewardship to create a better patient care pathway for diagnosis of bloodstream infections IDWeek Learning Lounge, Washington, DC	10/2019
Clinical and economic benefits of sustaining and expanding stewardship programs American College of Clinical Pharmacy, Global Conference, Seattle, WA	10/2018
Clinical Insights: Strategic implementation of a rapid molecular blood culture panel for gram-negative bacteremia XTalks Webinar, online	10/2018
Developing a risk assessment tool for MRSA ABSSSI Bayer International Global Council Meeting, Copenhagen, Denmark	05/2015

STATE & LOCAL PRESENTATIONS

Antimicrobial susceptibility testing and antimicrobial therapy decisions University of Maryland Medical Center, Pediatric Infectious Diseases Grand Rounds	09/2023
----------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------

Best practices for diagnosis and management of UTIs and ASB Maryland SPARC Antibiotic Stewardship Collaborative, webinar, online	07/2023
Introduction to clinical research University of Maryland Medical Center & School of Pharmacy, Baltimore, MD	07/2023
From premise to paper: Successfully publishing resident research projects University of Maryland Medical Center Preceptor Development Series, Baltimore, MD	12/2022
Optimizing rapid diagnostic tests for the management of bloodstream infections Maryland Statewide Prevention and Reduction of <i>C. difficile</i> Collaborative (SPARC), webinar, online	07/2019
The basic of infectious diseases management in hospice and palliative care Hospice & Palliative Care Medical Director's Symposium, Columbia, MD	05/2019
How to measure the effectiveness of incorporating antibiogram data at your facility Peter Lamy Center on Drug Therapy and Aging Webinar, online	02/2019
Use of rapid diagnostic test in bloodstream infections to improve patient outcomes and antimicrobial stewardship initiatives University of Maryland School of Pharmacy, Baltimore, MD	01/2019
Applying appropriate biostatistics for clinical research University of Maryland Medical Center Preceptor Development Series, Baltimore, MD	11/2018
Microbiology, antibiograms, and anti-infective basics 101 Maryland Long Term Care Antimicrobial Stewardship Summit, September 2018, Columbia, MD	09/2018
Improving clinical outcomes in gram- negative bacteremia through a multidisciplinary rapid diagnostic treatment pathway Maryland CAAUSE Antibiotic Stewardship Meeting, Baltimore, MD	03/2018
Back to Basics – Dosing of Aminoglycosides Maryland Society of Health-Systems Pharmacists Infectious Disease CE Dinner, Baltimore, MD	09/2016

MEDIA CONTRIBUTIONS

1. *When should we still use vancomycin?* SHEA Podcast. February 2024
2. *Reducing Downstream Antibiotic Use.* [National Academy of Medicine](#): NAM Scholars in Dx Ex. September 2023
3. *'Reflex Culture' May Be Cure for ID Lab Test Overreliance.* [Pharmacy Practice News](#). September 2023

4. Harnessing Speed for Health: Understanding Rapid Diagnostic Technologies for Infectious Diseases. [Infectious Disease Special Edition](#). August 2023
5. *The Three Phases of Implementing Diagnostic Stewardship*. [Infectious Disease Special Edition](#). July 2023
6. *Behavior Change to Improve Diagnosis*. National Academy of Medicine, Scholars in Diagnostic Excellence Podcast. May 2023
7. *Teaming Up with Clinical Microbiology for a Diagnostic Stewardship Program*. [Infectious Disease Special Edition](#). July 2022
8. The next big thing in stewardship? [Contagion Live](#). May 2022
9. *The impact of diagnostics on antimicrobial decisions: Three rapid panels put to the DOOR-MAT test*. [CAP Today](#). April 2022
10. *Expert Updates in Gram Negative Resistance: Q & A Session*. Breakpoints: SIDP Podcast. July 2020
11. *Most institutions use rapid viral tests, but stewardship practices are uncommon*. [Infectious Diseases News](#). December 2020
12. *Rapid diagnostics for gram-negative bloodstream infections*. [Pharmacy Times Contagion Live](#). June 2019
13. *Why ID? Experts Share The 'Why' That Drove Them to Pursue Infectious Disease Careers*. [Pharmacy Times Contagion Live](#). May 2019
14. *Evaluating rapid diagnostics for bloodstream infections without stewardship involvement*. [Pharmacy Times Contagion Live](#). May 2019
15. *Treatment algorithm an asset for antibiotic stewardship*. [Infectious Diseases News](#). October 2018
16. *Novel cephalosporin agent with broad gram-negative activity shows promise in clinical trial for complicated urinary tract infections*. [Pharmacy Times Contagion Live](#). December 2017
17. *Reality versus expectation: Being an Infectious Diseases Pharmacy Fellow*. [ID Stewardship](#). August 2016

AWARDS & RECOGNITION

Early Career Investigator Award Society of Infectious Diseases Pharmacists (SIDP)	10/2022
Health-System Pharmacist of the Year Maryland Society of Health-System Pharmacists (MSHP)	09/2022
Peer Reviewer of the Year American College of Clinical Pharmacy Pharmacotherapy (ACCP)	10/2019
Young Scientist Research Travel Grant European Congress of Clinical Microbiology and Infectious Diseases	02/2018

Trainee Travel Grant Making a Difference in Infectious Disease (MAD-ID)	04/2015
Infectious Disease Fellows Grant Program Interscience Conference on Antimicrobial Agents and Chemotherapy	06/2014
Young Scientist Research Travel Grant European Congress of Clinical Microbiology and Infectious Diseases	02/2014
Richard A. Hutchinson Award for Excellence in Pharmacy Practice University of Illinois at Chicago College of Pharmacy	06/2013
Award for Outstanding Professional and Community Service Eugene Applebaum College of Pharmacy and Health Sciences	05/2012
Student Research Award Southeastern Michigan Society of Health-System Pharmacists	11/2011
Good Government Award Michigan Pharmacists Association	02/2011

LICENSURE & CERTIFICATIONS

Registered Pharmacist License No. 24048 Maryland Department of Health and Mental Hygiene	04/2016 – present
Registered Pharmacist License No. 051296192 Illinois Department of Financial and Professional Regulation	09/2012 – present
Antimicrobial Stewardship Certificate Program Society of Infectious Diseases Pharmacy	09/2015 – 05/2016
Board Certified Pharmacotherapy Specialist Board of Pharmacy Specialties	12/2013 – 12/2020
Basic Cardiac Life Support Certification American Heart Association	07/2012 – present

PROFESSIONAL MEMBERSHIP

The Society for Healthcare Epidemiology of America	2017 – present
Maryland Society of Health-System Pharmacists	2016 – present
Infectious Diseases Society of America	2014 – 2016
European Society of Clinical Microbiology and Infectious Diseases	2013 – present
Society of Infectious Diseases Pharmacists	2013 – present
American College of Clinical Pharmacy	2011 – present